Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-centre Randomised Study of Induction Chemotherapy Followed by Capecitabine (+/-Nelfinavir) With High or Standard Dose Radiotherapy for Locally Advanced Non-metastatic Pancreatic Cancer

Next Previous
Trial Profile

A Multi-centre Randomised Study of Induction Chemotherapy Followed by Capecitabine (+/-Nelfinavir) With High or Standard Dose Radiotherapy for Locally Advanced Non-metastatic Pancreatic Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelfinavir (Primary) ; Capecitabine; Gemcitabine; Paclitaxel
  • Indications Carcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SCALOP-2

Most Recent Events

  • 25 Jul 2024 Arms decreased from 5 to 4. Experimental: Arm E cancelled.
  • 01 Jun 2021 Status changed from active, no longer recruiting to completed.
  • 10 Jun 2020 Status changed from suspended to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top